Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway

Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors

Study: Casdatifan, a new generation HIF-2α blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer. The findings link treatment activity to HIF-2α biology and biomarker changes, supporting precision medicine approaches.

A University of Texas at Dallas researcher has received more than $1 million in grants from the Cancer Prevention & Research Institute of Texas (CPRIT) to develop treatments for solitary fibrous tumor, or SFT. The rare cancer develops when two genes, NAB2 and STAT6, become fused together, resulting in signals that initiate cancer-cell growth. The cause is unknown. While no medications have been developed specifically for SFT, treatment typically involves surgery to remove the tumor and/or radiation.

Marlon L. Wong, P.T., Ph.D., associate professor of clinical physical therapy at the University of Miami Miller School of Medicine, has been awarded a grant from Gabrielle’s Angel Foundation for Cancer Research. The award will support research focused on improving quality of life for patients living with chemotherapy-induced peripheral neuropathy and other long-term effects of cancer treatment. 

Researchers have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.

Plant-based diets are good for you.

In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.

Published today in Nature Communications, the study introduces PROTEXI, an innovative dendritic cell vaccine platform designed to harness pre-existing antiviral immune memory to amplify the body's natural ability to recognize and destroy tumors.

As cigarette smoking reaches historic lows in the United States, new research from MUSC Hollings Cancer Center shows that many younger adults are replacing cigarettes with noncombustible nicotine products, particularly e-cigarettes, rather than quitting tobacco altogether. An analysis of national survey data found that while overall tobacco use has remained relatively stable, combustible tobacco use has declined sharply, especially among adults ages 18 to 34. Researchers also developed a new population harm-reduction index suggesting this shift could substantially reduce future tobacco-related cancers if it continues. However, the study found that older adults who smoke are far less likely to switch away from combustible tobacco, highlighting an important opportunity for tobacco cessation and harm-reduction efforts.